Pfizer Ltd. — Regulatory Filings 2023

May 15, 2023

==> picture [94 x 40] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 15, 2023

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Dalal Street, Fort Plot No. C/1, G Block Mumbai – 400 001 Bandra-Kurla Complex, Bandra (E) Scrip Code: 500680 Mumbai – 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’)

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2023.

The said disclosure is also available on the website of the Company i.e., www.pfizerltd.co.in

We request you to kindly take the same on record.

Thanking you,

Yours truly, For Pfizer Limited

PRAJEET Digitally signed by PRAJEET NAIR NAIR Date: 2023.05.15 19:51:33 +05'30' Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

Pfizer Limited - Statement of Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015

Rs. In Crores

==> picture [686 x 219] intentionally omitted <==

----- Start of picture text -----

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-
corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only
once, during the reporting period when such transaction was undertaken.
Sr. Details of the party Details of the counter party Type of related party transaction Value of the related party Remarks on approval by Audit Value of transaction In case monies are due to either party as In case any financial indebtedness is Details of the loans, inter-corporate deposits, advances or investments
no listed entity entering into the transaction as approved Committee during the reporting a result of the transaction incurred to make or give loans, inter-
transaction by the audit committee period corporate deposits, advances or
investments
Name PAN Name PAN Relationship of the counterparty with Opening balance Closing balance Nature of indebtedness Cost Tenure Nature (loan/ advance/ Interest Tenure Secured/ Purpose for which the
the listed entity or its subsidiary (loan/ issuance of debt/ any inter- corporate deposit/ Rate (%) unsecured funds will be utilised by the
other etc.) investment ultimate recipient of funds
(end- usage)
1 Pfizer Limited AAACP3334M Pfizer Service Company BVBA, Belgium ZZZZZ9999Z Fellow subsidiary Purchase of goods & services 220.59 On arm's length basis and in 220.59 33.53 83.56 Not Applicable
Ordinary course of business
2 Pfizer Limited AAACP3334M Pfizer Healthcare India Private Limited AABCO2190F Fellow subsidiary Service income 1.78 On arm's length basis and in 1.78 -1.97 -4.05 Not Applicable
Ordinary course of business
3 Pfizer Limited AAACP3334M Pfizer Products India Private Limited AADCP8985B Fellow subsidiary Service income 8.64 On arm's length basis and in 8.64 -10.02 -9.58 Not Applicable
Ordinary course of business
4 Pfizer Limited AAACP3334M Pfizer Export B.V. ZZZZZ9999Z Fellow subsidiary Service Income 0.09 On arm's length basis and in 0.09 -0.32 - Not Applicable
Ordinary course of business
5 Pfizer Limited AAACP3334M Pfizer Worldwide Services Company ZZZZZ9999Z Fellow subsidiary Service income 34.03 On arm's length basis and in 34.03 -33.27 -20.19 Not Applicable
Ordinary course of business
6 Pfizer Limited AAACP3334M Pfizer Products India Private Limited AADCP8985B Fellow subsidiary Recovery of expense 0.14 On arm's length basis and in 0.14 - - Not Applicable
Ordinary course of business
7 Pfizer Limited AAACP3334M John Wyeth & Brothers Ltd ZZZZZ9999Z Company collectively exercising Recovery of expense 0.03 On arm's length basis and in 0.03 2.50 2.50 Not Applicable
significant influence Ordinary course of business
8 Pfizer Limited AAACP3334M Mr. Pradip Shah AADPN9155G Independent Director Sitting Fees 0.03 On arm's length basis and in 0.03 - - Not Applicable
Ordinary course of business
9 Pfizer Limited AAACP3334M Mr. Uday Khanna AFEPK7061E Independent Director Sitting Fees 0.03 On arm's length basis and in 0.03 - - Not Applicable
Ordinary course of business
10 Pfizer Limited AAACP3334M Mr. Sunil Lalbhai AAFPL0691R Independent Director Sitting Fees 0.03 On arm's length basis and in 0.03 - - Not Applicable
Ordinary course of business
11 Pfizer Limited AAACP3334M Ms. Meena Ganesh ABPPG1456L Independent Director Sitting Fees 0.02 On arm's length basis and in 0.02 - - Not Applicable
Ordinary course of business
12 Pfizer Limited AAACP3334M Mr. S. Sridhar AAHPS2626R Key Managerial Personnel Remuneration 3.89 On arm's length basis and in 3.89 - - Not Applicable
Ordinary course of business
13 Pfizer Limited AAACP3334M Mr. Milind Patil AAEPP3949B Key Managerial Personnel Remuneration 1.45 On arm's length basis and in 1.45 - - Not Applicable
Ordinary course of business
14 Pfizer Limited AAACP3334M Mr. Samir Kazi AJSPK0243Q Key Managerial Personnel Remuneration 1.62 On arm's length basis and in 1.62 - - Not Applicable
Ordinary course of business
15 Pfizer Limited AAACP3334M Mr. Prajeet Nair AADPN9155G Key Managerial Personnel Remuneration 0.49 On arm's length basis and in 0.49 - - Not Applicable
Ordinary course of business
----- End of picture text -----